Harvard Pilgrim Health Care | TUFTS Health Plan

Medical Necessity Guidelines
Medical Benefit Drugs

Breyanzi® (lisocabtagene maraleucel)

Effective: March 1, 2024

Prior Authorization Required If REQUIRED, submit supporting clinical documentation pertinent to service request.	Yes ☒ No ☐

Applies to:

Commercial Products

☒ Harvard Pilgrim Health Care Commercial products; Fax 617-673-0988
☒ Tufts Health Plan Commercial products; Fax 617-673-0988
CareLink℠ – Refer to CareLink Procedures, Services and Items Requiring Prior Authorization

Public Plans Products

☒ Tufts Health Direct – A Massachusetts Qualified Health Plan (QHP) (a commercial product); Fax 617-673-0988
☐ Tufts Health Together – MassHealth MCO Plan and Accountable Care Partnership Plans; Fax 617-673-0939
☒ Tufts Health RITogether – A Rhode Island Medicaid Plan; Fax 617-673-0939
☐ Tufts Health One Care-- A dual-eligible product; Fax 617-673-0956

Senior Products

☐ Harvard Pilgrim Health Care Stride Medicare Advantage; Fax 617-673-0956
☐ Tufts Health Plan Senior Care Options (SCO), (a dual-eligible product); Fax 617-673-0956
☐ Tufts Medicare Preferred HMO, (a Medicare Advantage product); Fax 617-673-0956
☐ Tufts Medicare Preferred PPO, (a Medicare Advantage product); Fax 617-673-0956

Note: While you may not be the provider responsible for obtaining prior authorization, as a condition of payment you will need to ensure that prior authorization has been obtained.

Overview

Chimeric antigen receptor T-cell therapy (CAR-T cell therapy), a type of immunotherapy which may also be referred to as adoptive T-cell therapy, attempts to program patients' own immune systems to recognize and attack cancer cells. The first step in this therapy is to remove T-cells from the patient via apheresis, a process that removes blood from the body and removes one or more blood components (such as white blood cells, plasma, or platelets). The remaining blood is then returned to the body. The T-cells are then sent to a drug manufacturing facility or laboratory where they are genetically engineered to produce chimeric antigen receptors (CARs) on their surface. These CARs are what allow the T-cells to recognize an antigen on targeted tumor cells. The genetically modified T-cells are grown in the lab until there are enough of them (many millions) to freeze and return to the center treating the patient. There they are infused into the recipient with the expectation that the CAR T cells will recognize and kill cancerous cells that have the targeted antigen on their surface. Since the CAR-T cells may remain in the body long after the infusion, it is possible the treatment can bring about long-term remission. CAR-T cell therapy can be used to treat certain hematologic malignancies when the disease is relapsed or refractory to standard line(s) of treatment.

Food and Drug Administration (FDA) Approved Indications:

BREYANZI (lisocabtagene maraleucel) is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who have:

- Refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy
- Refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age
- Relapsed or refractory disease after two or more lines of systemic therapy

Breyanzi is not indicated for the treatment of patients with primary central nervous system lymphoma.

REMS Program: BREYANZI is available only under a restricted program called BREYANZI REMS because of the serious risks of Cytokine Release Syndrome (CRS) and neurologic toxicities. The goals of BREYANZI REMS are to mitigate the risks of CRS and neurologic toxicities by:

- Ensuring that hospitals and associated clinics that dispense BREYANZI are specially certified and have on-site immediate access to tocilizumab.
- Ensuring that those who prescribe, dispense, or administer BREYANZI are aware of how to manage the risks of CRS and neurologic toxicities

For more information about the BREYANZI REMS program, call 1-888-423-5436 or go to https://www.breyanzirems.com/

Clinical Guideline Coverage Criteria

The Plan may cover Breyanzi for Members aged 18 years or over when all of the following clinical criteria are met:

1. The Member has been diagnosed with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B

AND

2. Who have **one** of the following:
   a. Refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy
   b. Refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age
   c. Relapsed or refractory disease after two or more liens of systemic therapy

   * Relapsed/Refractory defined as disease progression after last the treatment regimen or refractory/suboptimal response to the most recent therapy

AND

3. Member's previous treatments, unless contraindicated, must have included but are not limited to **all** of the following drug therapies:
   a. A CD20-targeted agent (e.g., rituximab)

   AND

   b. Anthracycline-based chemotherapy (e.g., doxorubicin, epirubicin)

AND

4. The Member does not have primary central nervous system (CNS) lymphoma

AND

5. The Member has adequate organ function including bone marrow, cardiac, pulmonary, , and neurological with no anticipated decline in organ function in close proximity to apheresis timeframe

AND

6. The Member does not have active infection or inflammatory condition

AND

7. For Members with a history of allogeneic stem cell transplantation, there is no indication of active graft vs. host disease (GVHD)

AND

8. The Member has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

AND

9. The treating facility is certified under the Risk Evaluation and Mitigation Strategy (REMS) System program for Breyanzi.

NOTE: Documentation submitted must list previous lines of treatment/systemic therapies and date of each therapy

In addition to the above criteria, the Plan may cover Breyanzi in an outpatient setting when all of the following criteria is met:

1. The provider attests that they have assessed the Member and determined that outpatient administration is clinically appropriate.

2. The provider attests that the Member meets and understands the requirements of safety and monitoring post infusion as described by the Breyanzi REMS program[1].

Note: Prior authorization for Breyanzi is required regardless of hospital inpatient or outpatient setting.

Limitations

- Breyanzi therapy is contraindicated in pregnancy.
- Members receiving immunosuppressive therapy for an autoimmune disorder will not be approved for Breyanzi therapy.
- Members with untreated underlying primary immunodeficiency syndromes will not be approved for Breyanzi therapy.
- Members with active and/or metastatic malignancy that is unlikely to respond to treatment will not be approved for Breyanzi therapy.
- Authorization of Breyanzi therapy is limited to a single dose.
- Members who have had prior treatment with any form of CAR-T cell therapy, including therapies in clinical trial settings, will not be approved for additional CAR-T therapy.
- Breyanzi therapy will not be covered if the Member demonstrates clinical decompensation from time of authorization to time of infusion and no longer meets clinical coverage criteria.
- Any indications for Breyanzi therapy other than those outlined above are considered investigational and will not be covered

ECOG Performance Status:

- 0: Fully active, no restrictions on activities. A performance status of 0 means no restrictions in the sense that someone is able to do *everything* they were able to do prior to their diagnosis.
- 1: Unable to do strenuous activities, but able to carry out light housework and sedentary activities. This status basically means you can't do heavy work but can do anything else.
- 2: Able to walk and manage self-care, but unable to work. Out of bed more than 50% of waking hours. In this category, people are usually unable to carry on any work activities, including light office work.
- 3: Confined to bed or a chair more than 50 percent of waking hours. Capable of limited self-care.
- 4: Completely disabled. Totally confined to a bed or chair. Unable to do any self-care.
- 5: Death

Codes

The following code(s) require prior authorization:

Table 1: HCPCS Codes

HCPCS Codes	Description
Q2054	Lisocabtagene maraleucel, up to 110 million autologous anti-CD19 CAR-positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic doses

Table 2: CPT Codes

CPT Codes	Description
0537T	Chimeric antigen receptor T-cell (CAR-T) therapy; harvesting of blood-derived T lymphocytes for development of genetically modified autologous CAR-T cells, per day
0538T	Chimeric antigen receptor T-cell (CAR-T) therapy; preparation of blood-derived T lymphocytes for transportation (e.g., cryopreservation, storage)
0539T	Chimeric antigen receptor T-cell (CAR-T) therapy; receipt and preparation of CAR-T cells for administration
0540T	Chimeric antigen receptor T-cell (CAR-T) therapy; CAR-T cell administration, autologous

References:

1. Bristol Myers Squibb. (2023, April 1). *Risk Evaluation and Mitigation Strategy (REMS)*. Breyanzi Rems. https://www.breyanzirems.com/index.html

2. Hayes, Inc. Medical Technology Directory Report. Adoptive Immunotherapy Using Genetically Modified Lymphocytes for Lymphoproliferative Disorders and Hematological Malignancies. September 7, 2017. Available at hayesinc.com. Last accessed October 26, 2017.
3. Hansen, D. K., Liu, Y. H., Ranjan, S., Bhandari, H., Potluri, R., McFarland, L., De Braganca, K. C., & Huo, S. (2023). The Impact of Outpatient versus Inpatient Administration of CAR-T Therapies on Clinical, Economic, and Humanistic Outcomes in Patients with Hematological Cancer: A Systematic Literature Review. Cancers, 15(24), 5746. https://doi.org/10.3390/cancers15245746
4. United States Department of Health and Human Services, National Institutes of Health, National Cancer Institute. CAR-T Cells: Engineering Patients' Immune Cells to Treat Their Cancers. Available at cancer.gov. Last accessed October 24, 2017.
5. Leukemia & Lymphoma Society. Chimeric Antigen Receptor (CAR) T-Cell Therapy Facts. Available at lls.org. Last accessed October 20, 2017.
6. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. *N Engl J Med*. 2020;382(14):1331-1342. doi:10.1056/NEJMoa1914347.
7. Initial treatment of mantle cell lymphoma. UpToDate.com/login [via subscription only]. Accessed: July 30, 2020.
8. United States Food and Drug Administration. Package Insert-BREYZANI. Available at fda.gov. June 2022.
9. Abramson JS, Palomba ML, et. al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicenter seamless design study. Lancet. 2020 Sep 19;396(10254):839-852. doi: 10.1016/S0140-6736(20)31366-0. Epub 2020 Sep 1. PMID: 32888407.
10. Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2015;26 Suppl 5:v116-v125. doi:10.1093/annonc/mdv304.
11. Freedman AS, MD, Friedbery JW, MD. Relapsed or refractory diffuse large B cell lymphoma. UpToDate last accessed June 21, 2021. uptodate.com/contents/relapsed-or-refractory-diffuse-large-b-cell-lymphoma/print?search=CD-19%20positive%20relapsed%20or%20refractory%20large%20B-cell%20lymphoma,&topicRef=4729&source=see_link#.
12. Center for Medicare and Medicaid National Coverage Determination (NCD) for Chimeric Antigen Receptor (CAR) T-cell Therapy (110.24) last accessed June 28, 2021 at NCD - Chimeric Antigen Receptor (CAR) T-cell Therapy (110.24) (cms.gov)
13. National Comprehensive Cancer Network. Diffuse Large B-Cell Lymphoma (Version 4.2021). nccn.org/professionals/physician_gls/pdf/b-cell_blocks.pdf. Accessed July 9, 2021.
14. Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukemia: phase 2 results of the single-arm, open-label, multicenter ZUMA-3 study. Lancet. 2021;398(10299):491-502. doi:10.1016/S0140-6736(21)01222-8
15. Trando A, Ter-Zakarian A, Yeung P, et al. Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Large B-Cell Lymphoma (LBCL): A Single-Institution Experience. *Cancers (Basel)*. 2023;15(18):4671. Published 2023 Sep 21. doi:10.3390/cancers15184671

Approval And Revision History

September 21, 2022: Reviewed by the Medical Policy Approval Committee (MPAC)

Subsequent endorsement date(s) and changes made:

- Originally approved at September 21, 2022 MPAC effective January 1, 2023
- Administrative update: November 2023 added Medical Benefit Drugs to title, updated MATogether and RITogether fax numbers to 617-673-0939, and change Unify name to One Care effective January 1, 2024
- November 16, 2023: Reviewed by MPAC, renewed without changes effective January 1, 2024
- January 17, 2024: Reviewed by MPAC, added language to allow for contraindication to previous treatment, updated organ function criteria question, added criteria for allow for outpatient administration, updated ECOG from 0-1 to 0-2, removed history of CNS disease limitation, and updated references effective March 1, 2024

Background, Product and Disclaimer Information

Medical Necessity Guidelines are developed to determine coverage for benefits and are published to provide a better understanding of the basis upon which coverage decisions are made. We make coverage decisions using these guidelines, along with the Member's benefit document, and in coordination with the Member's physician(s) on a case-by-case basis considering the individual Member's health care needs.

Medical Necessity Guidelines are developed for selected therapeutic or diagnostic services found to be safe and proven effective in a limited, defined population of patients or clinical circumstances. They include concise clinical coverage criteria based on current literature review, consultation with practicing physicians in our service area who are medical experts in the particular field, FDA and other government agency policies, and standards adopted by national accreditation organizations. We revise and update

Medical Necessity Guidelines annually, or more frequently if new evidence becomes available that suggests needed revisions.

For self-insured plans, coverage may vary depending on the terms of the benefit document. If a discrepancy exists between a Medical Necessity Guideline and a self-insured Member's benefit document, the provisions of the benefit document will govern. For Tufts Health Together (Medicaid), coverage may be available beyond these guidelines for pediatric members under age 21 under the Early and Periodic Screening, Diagnostic and Treatment (EPSDT) benefits of the plan in accordance with 130 CMR 450.140 and 130 CMR 447.000, and with prior authorization.

Treating providers are solely responsible for the medical advice and treatment of Members. The use of this guideline is not a guarantee of payment or a final prediction of how specific claim(s) will be adjudicated. Claims payment is subject to eligibility and benefits on the date of service, coordination of benefits, referral/authorization, utilization management guidelines when applicable, and adherence to plan policies, plan procedures, and claims editing logic.